FRA
RLMD icon

Front Row Advisors’s Relmada Therapeutics RLMD Stock Holding History

Front Row Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9 Buy
+2
New +$14 ﹤0.01% 572
2026
Q1 		– Sell
-2
Closed -$10 – 567
2025
Q4 		$10 Hold
2
– – ﹤0.01% 549
2025
Q3 		$4 Sell
2
-1
-33% -$1 ﹤0.01% 551
2025
Q2 		$2 Sell
3
-3
-50% -$2 ﹤0.01% 538
2025
Q1 		$2 Buy
+6
New +$2 ﹤0.01% 511
2024
Q4 		– Sell
-6
Closed -$19 – 506
2024
Q3 		$19 Hold
6
– – ﹤0.01% 499
2024
Q2 		$18 Hold
6
– – ﹤0.01% 937
2024
Q1 		$28 Hold
6
– – ﹤0.01% 923
2023
Q4 		$25 Hold
6
– – ﹤0.01% 469
2023
Q3 		$18 Hold
6
– – ﹤0.01% 916
2023
Q2 		$0 Hold
6
– – ﹤0.01% 942
2023
Q1 		$0 Buy
+6
New +$21 ﹤0.01% 946

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Front Row Advisors's RLMD Position: Q2 2026 in Review

Front Row Advisors opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 2 shares worth $9. The stake represents ﹤0.01% of the portfolio and ranks #572 among its holdings. This is a return to the name: Front Row Advisors previously reported a position in RLMD as recently as Q4 2025.

Front Row Advisors first reported a position in RLMD in Q1 2023 and has held it in 12 quarters since. The position peaked at $28 in Q1 2024. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Front Row Advisors held 2 shares of Relmada Therapeutics worth $9 as of Q2 2026.
  • Relmada Therapeutics was a new Front Row Advisors position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #572 holding.
  • Front Row Advisors first reported a position in Relmada Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Front Row Advisors's Relmada Therapeutics position peaked at $28 in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.